In contrast, the combination of peposertib with the LSD-1 inhibitor iadademstat resulted in sub-additive to additive cell killing in the five PDMR lines highlighted, 186277-243-T-J2 and 233499-124-R-J3 colon carcinomas, 324938-238-R-1 bladder carcinoma, 743899-274-T renal cell carcinoma and 521955-158-R2-J5 pancreatic carcinoma (Figure 5A). Here, KDM1A is linked to renal cell carcinoma.